ACRS
NASDAQ:ACRSNASDAQ
1 announcements
Credibility Score100%
Aclaris Therapeutics Announces Top Line Phase 2 Results for its Anti-TSLP Monoclonal Antibody Bosakitug (ATI-045) in Atopic Dermatitis (AD)
Routineunclear
Aclaris' lead antibody failed Phase 2, shifting focus to other pipeline assets.
about 3 hours ago
▼